Ukoniq™ (Umbralisib) Is Available Exclusively From Onco360!
“UKONIQ is the first and only, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon. Accelerated approval was granted for these indications based on overall response rate (ORR) data from the Phase 2 UNITY-NHL Trial (NCT02793583). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial. This application was granted priority review for the MZL indication. In addition, UKONIQ was granted Breakthrough Therapy Designation (BTD) for the treatment of MZL and orphan drug designation (ODD) for the treatment of MZL and FL.”1
UKONIQ™ is a kinase inhibitor indicated for the treatment of adult patients with:
Dosage and Administration
Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Dosage Forms and Strengths1
UKONIQ is available in 200 mg tablets (NDC 73150-200-12).
Community and hospital-based oncologists can immediately place prescription orders for UKONIQ, as well as other cancer and supportive care medications.
2 UKONIQ prescribing information: TG Therapeutics. UKONIQ trademark is owned or licensed by TG Therapeutics.